Matches 151 - 200 out of 239 < 1 2 3 4 5 >
Match Document Document Title
5580580 Formulations and their use in the treatment of neurological diseases  
Pharmaceutical formulations comprise a mono- or di-aminopyridine active agent for administration on a once- or twice-daily basis for use in the treatment of neurological diseases, in particular...
5576019 Method for blinding a medication  
The invention relates to a method for making and administering a blinded oral dosage form and the blinded oral dosage form therefor, used for disguising the identity of tableted medications. The...
5567438 Shellac dispersions and coatings, and method of forming aqueous-based shellac dispersions and coatings  
A method of forming the aqueous-based shellac dispersion includes dissolving a shellac solution in a basic aqueous solvent to form a shellac solution and subsequently combining the shellac solution...
5558878 Method for blinding a tableted medication  
The invention relates to a method for making and administering a blinded oral dosage form and the blinded oral dosage form therefor, used for disguising the identity of tableted medications. The...
5527542 Process for sugarless coating and products obtained according to the process  
The present invention relates to a process for coating with maltitol making it possible easily and rapidly to create a coating on the surface of a product. This process consists, on the one hand,...
5525354 Pharmaceutical preparation and process for its manufacture  
In a pharmaceutical preparation for oral use containing a pharmacologically acceptable salt of a bisphosphonic acid, the improvement comprising: a drug delivery form of the preparation which is...
RE35200 Coating for pharmaceutical dosage forms  
Coated pharmaceutical dosage forms which are resistant to gastric juice and release their active ingredient rapidly at a predetermined pH value in the range from pH 5 to pH 8 are obtained in...
5487901 Process for preparing pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times  
A pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times produced via the steps of: a) preparing a tablet consisting of three superposed layers, the...
5472710 Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture  
Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture. Pharmaceutical preparation to be administered orally with controlled...
5470581 Aqueous maltodextrin and cellulosic polymer film coatings  
A method of coating substrates such as pharmaceutical tablets, food and confectionery forms, agricultural seeds and the like, with a protective film comprises the steps of mixing a cellulosic...
5464633 Pharmaceutical tablets releasing the active substance after a definite period of time  
Pharmaceutical tablets releasing the active substance after a definite period of time, consisting of: a core containing the active substance and polymeric substances which swell and/or gel and/or...
5445829 Extended release pharmaceutical formulations  
An extended release pharmaceutical formulation adapted to approach zero order release of drug over a 12 to at least 24 hour period, comprised of a mixture of 0 to about 50% of an immediate release...
5439941 Use of alkyl cyclopentanone and phenyl alkanol derivative-containing compositions for repelling blood feeding arthropods and apparatus for determining repellency and attractancy of semiochemicals against and for blood feeding arthropods  
Described is an insect repelling detergent tablet consisting of (A) a polymeric core containing a microporous polymer containing in the interstices thereof an effective insect repelling amount...
5425950 Controlled release pharmaceutical compositions  
This invention relates to a controlled release pharmaceutical composition comprising: (a) an outer layer comprising a pH independent hydrophilic polymer together with one or more fillers; and (b)...
5422122 Controlled release potassium chloride tablet  
A pharmaceutical dosage form is prepared from a multiplicity of coated potassium chloride crystals coated with two distinct layers, the first of ethylcellulose and the second of a hydrophilic...
5422121 Oral dosage unit form  
Coating agents comprising a liquid phase, a polysaccharide decomposable in the colon, such as locust bean gum or guar gum, and a film forming polymer preferably having hydrophilic groups, which...
5422115 Methods of treatment and devices employing lithium salts  
Methods of treatment of the human or animal body are provided to combat conditions responsive to lithium and/or C 18 -22 polyunsaturated fatty acid therapy, including conditions associated with...
5409709 Antipyretic analgesic preparation containing ibuprofen  
An ibuprofen-containing antipyretic analgesic preparation blending 0.01-30 parts by weight of acetaminophen based on 1 part by weight of ibuprofen, 0.05-100 parts by weight of magnesium-based...
5401515 Coated active agent-containing article  
Aqueous coating compositions for forming elastomeric films around active cores (e.g., drugs) comprising a dispersion of pre-crosslinked polyorganosiloxane latex particles, colloidal silica...
5393532 Process for preparing a phenylalanine-free dietary product in dragee or tablet form  
The invention pertains to a process for preparing a phenylalanine-free dietetic product comprising L-amino acids, and optionally comprising carbohydrates, minerals, trace elements and/or vitamins,...
5393333 Film-forming product for coating solid forms, process for its manufacture and products coated with this film-forming product  
The present invention relates to a film-forming product for coating solid forms, to a process for the manufacture of this film-forming product and to products coated with this film-forming product....
5324522 Sustained release thyroactive composition  
Disclosed are sustained release dosage forms of liothyronine, in combination with normal or sustained release of thyroxine in a molar ratio of about 1 to 50:1, especially 5 to 20:1, useful in...
5322698 Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure  
The invention relates to a process for the preparation of a tablet or dragee composition containing a moisture-, heat- and light-sensitive compounds having monoclinic crystalline structure as...
5314696 Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor  
The invention relates to a method for making and administering a blinded oral dosage form and the blinded oral dosage form therefor, used for disguising the identity of tableted medications. The...
5314697 Stable extended release oral dosage composition comprising loratadine and pseudoephedrine  
A film-coated extended release oral dosage composition containing the nasal decongestant pseudoephedrine sulfate in a unique polymer matrix core and a film-coating on such core containing the...
5294448 Delayed release formulations  
Delayed release compositions comprising an active compound and amorphous amylose and having an outer coating comprising a film forming cellulose or acrylic polymer material, for example glassy...
5271946 Controlled release azelastine-containing pharmaceutical compositions  
Azelastine-containing pharmaceutical compositions which provide controlled release of the active substance using a sustained release component. The compositions contain azelastine or a...
5268181 Method of using niacin to control nocturnal cholesterol synthesis  
The invention provides a therapeutic method to treat hyperlipidemia by administering to a human patient a single daily dose of a prolonged release dosage form of niacin, so that nocturnal...
5266320 Aminovinyl-substituted heterocyclic compounds as stabilizers for organic materials  
The use of an aminovinyl-substituted heterocyclic compound of the general formula I ##STR1## in which R 1 denotes hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, or halogen, and, if more than one...
5262169 Tablets and granulates containing mesna as active substance  
A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other...
5258436 Film-forming composition; method of producing same and use for coating pharmaceuticals and foods and the like  
A water dispersible polymeric film-forming particulate composition for use in coating pharmaceuticals and foods or the like, produced by freeze-drying an aqueous solution of water-soluble cellulose...
5248505 Method for treating gastrointestinal distress  
This invention relates to a pharmaceutical composition for treating gastrointestinal distress comprising an effective amount of an antidiarrheal composition, e.g. loperamide, and an antiflatulent...
5240712 Therapeutic agents  
A high content of 2-(4-isobutylphenyl)propionic acid is achieved in a pharmaceutical composition by solidifying molten 2-(4-isobutylphenyl)propionic acid to provide a unit dose composition. The...
5232706 Oral pharmaceutical preparation containing omeprazol  
The preparation comprises a nucleus formed by a mixture of omeprazol or an alkali salt of omeprazol with a first basic compound; the nucleus has two coatings, the first of which is formed by one or...
5186937 Composition for feeding ruminants  
A composition which is stable in a medium in which the pH is greater than or equal to 5.5 and which permits the release of an active substance in a medium in which the pH is less than or equal to...
5178874 Intermittent release dosage form  
Veterinary delayed release dosage forms which remain in the rumeno-reticular sac of an animal over an extended period of time and in which the therapeutically active substance has a predictable and...
5162117 Controlled release flutamide composition  
A controlled release solid dosage tablet of flutamide is disclosed that is designed to provide an immediate release dose and a second delayed dose in pulsatile manner in the gastrointestinal tract...
5132295 Alginate-based verapamil-containing depot drug form  
An alginate-based depot drug form for which the rate of release of the active substance in vitro can be adjusted very precisely is described.
5128144 Pressing having sustained release of active compound  
Pressing having sustained release of active compound for the oral or parenteral administration of medicaments, which contains at least one solid pharmaceutical active compound, polylactic acid and...
5114720 Gelatin coated tablets and method for producing same  
Pharmaceutical tablets having increased slipperiness and swallowability are provided. The enhanced swallowability is imparted by an overcoat of a low bloom gelatin, which overcoat has a lower...
5091191 Pharmaceutical composition with improved dissolution property  
A pharmaceutical composition of the active agent sodium 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylb enzoate (a thromboxane synthetase inhibitor for treatment of diseases such as...
5085866 Method of producing zero-order controlled-released devices  
An improved method of producing a reservoir device having a rate-controlling membrane and zero-order (constant) release of an agent is provided. A core is sprayed with a solution having a polymer...
5047246 Direct compression cyclophosphamide tablet  
A directly compressible pharmaceutical composition comprising cyclophosphamide and a partially or fully pregelatinized starch is disclosed. The pharmaceutical composition, when directly compressed...
5025004 Water-dispersible polymeric compositions  
Disclosed is a process for preparing polymeric compositions which are suitable for coating medicaments or for use in cosmetic formulations and the novel compositions prepared therefrom. The process...
5023083 Azarbine composition  
A method for treating azaribine-responsive diseases in patient's who exhibit severe pyridoxal phosphate depletion following the oral administration of azaribine comprises first encapsulating...
5019398 Pharmaceutical composition providing the sustained-release of valproic acid  
The object of the invention is a tablet sustaining release for more than 8 hours, the active ingredient of which is constituted by the complex formed between one mole of valproic acid and one mole...
5017564 Solid pharmaceutical preparation and method of producing same  
Provided are a solid pharmaceutical preparation which contains disodium adenosine triphosphate together with a vitamin B 1 salt or the like and a method of treatment of human asthenopia by orally...
5017383 Method of producing fine coated pharmaceutical preparation  
A method of producing a fine coated pharmaceutical preparation, which includes cooling fine liquid droplets composed of a liquid medium, a drug dissolved or suspended in the liquid medium, and as...
5000962 Long acting diltiazem formulation  
A long acting diltiazem formulation is disclosed that comprises more than 35 percent by weight of a swellable hydrophilic polymer. Release rate is also controlled by the application of diffusion...
4999226 Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination  
The present invention is directed to a multi-layered tablet containing an ibuprofen layer, a piperidino-alkanol antihistamine layer, and a layer or layers containing conventional pharmaceutical...
Matches 151 - 200 out of 239 < 1 2 3 4 5 >